Digital download
Access the files immediately after checkout.
Myriad Marketing Mix
Included with this resource
Word + Excel files
Edit, adapt and present the analysis in familiar formats.
Complete marketing mix
Connect product, price, place and promotion.
Customer perspective
Review how each decision supports the target market.
Actionable choices
Turn the mix into practical marketing priorities.
Ready-Made Marketing Analysis, Ready to Use
Discover how Myriad’s product design, pricing architecture, channel strategy and promotional mix combine to create competitive advantage. This preview highlights key tactics and market positioning across the 4Ps. Get the full, editable Marketing Mix Analysis for detailed data, examples, and presentation-ready insights to save research time and boost strategic impact.
Product
Hereditary cancer risk panels
Myriad’s hereditary cancer risk panels use comprehensive multi-gene testing to detect inherited risk for breast, ovarian, colorectal and other cancers, with BRCA1/2 accounting for roughly 5–10% of breast cancers. Panels emphasize clinical validity, guideline-aligned actionable reports and deliver risk scores plus management insights for clinicians. Packaging includes intuitive, clinician-facing reports and integrated genetic counseling support.
Tumor profiling and companion diagnostics
Assays characterize tumor biomarkers to guide targeted therapies and inform prognosis, detecting actionable alterations in roughly 40–60% of advanced solid tumors. Tests are designed to meet companion diagnostic and regulatory standards. Reports highlight therapy matches and relevant clinical trials, and turnaround times are optimized for oncology workflows, typically 7–10 business days.
Women’s health genetic testing
Women’s health genetic testing by Myriad offers carrier screening panels covering 200+ conditions, prenatal diagnostics, and reproductive risk tests tailored for OB/GYN settings, supporting family planning and pregnancy management decisions. Results are delivered in clear reports with provider guides to streamline interpretation and clinical action. Patient education materials accompany testing to reduce uncertainty and increase adherence to recommended follow-up.
Pharmacogenomics for mental health
Pharmacogenomic testing guides antidepressant and psychotropic selection, aiming to improve the ~30–50% remission rate seen with first-line therapy by reducing nonresponse and side effects. Reports stratify gene–drug interactions into actionable bins (use as directed, consider alternative, avoid) and provider tools map results to prescribing actions; panels and labels are updated regularly to reflect new evidence and FDA label changes.
- Guides selection
- Actionable bins
- Prescriber tools/EHR
- Ongoing label updates
Digital tools and clinical support
Secure portals enable test ordering, tracking and results review while decision-support layers deliver guideline-aligned summaries and follow-up recommendations; Myriad pairs these with integrated tele-genetic counseling and patient support to boost adherence. Platforms are built with HIPAA and GDPR compliance and leverage the US genetic counseling workforce of over 5,000 professionals (NSGC 2024).
- Secure portals: ordering, tracking, results
- Decision support: guidelines, summaries, follow-up
- Integrated counseling: tele-genetics, patient support
- Security/compliance: HIPAA, GDPR
Integrated genomic testing: hereditary, tumor, carrier and PGx reports for faster care
Myriad’s product suite combines comprehensive hereditary cancer panels (BRCA1/2 ~5–10% of breast cancers), tumor biomarker assays detecting actionable alterations in ~40–60% of advanced solid tumors, 200+ condition carrier/prenatal panels, and pharmacogenomic reports reducing trial‑and‑error prescribing. Clinician reports, 7–10 business day oncology TAT, integrated tele‑genetics and HIPAA/GDPR compliance support clinical uptake.
| Product | Key metric | Impact |
|---|---|---|
| Hereditary panels | BRCA1/2 5–10% | Risk stratification |
| Tumor assays | 40–60% actionable | Therapy selection |
| Women’s health | 200+ conditions | Family planning |
| PGx | Improves initial remission* | Prescribing guidance |
| Delivery | 7–10 days; 5,000 GC (NSGC 2024) | Clinical integration |
What is included in the product
Detailed Word Document
Provides a company-specific deep dive into Myriad's Product, Price, Place, and Promotion strategies, using real brand practices and competitive context to highlight positioning, tactical examples, and strategic implications for managers, consultants, and marketers.
Customizable Excel Spreadsheet
Myriad 4P's condenses complex marketing strategy into a clean, customizable one‑pager—ideal for leadership briefings, team alignment, or rapid comparison across brands—saving time and clarifying priorities.
Place
Direct-to-clinician distribution
Sales and service teams engage oncologists, OB/GYNs, primary care, and psychiatrists to drive test adoption across specialty and general practice. Test kits are supplied to clinics with streamlined prepaid return logistics and centralized processing to reduce turnaround. Clinical liaisons support ordering workflows and result interpretation at point of care. Coverage prioritizes high-volume settings to maximize patient access and clinician uptake.
Hospital and health system partnerships
Embedded programs place testing into oncology and women’s health pathways, shortening clinical loops and aligning with multi-site systems that now include about 63% of US hospitals; co-developed workflows improve specimen handling and can cut NGS turnaround to a median of ~7 days; streamlined contracting eases roll-out across networks; secure data-sharing feeds quality initiatives and outcomes registries covering ~4,500 hospitals.
Digital portals and EHR integrations
Online ordering and real-time status tracking cut administrative friction for providers and patients, streamlining workflows and reducing call volume. EHR connectivity supports e-consent, automated eligibility checks and direct result delivery into charts; 96% of US hospitals use EHRs (ONC) and CMS mandated FHIR-based APIs in 2021. Embedded decision-support prompts increase guideline-concordant testing, and scalable APIs enable enterprise integrations.
Nationwide sample logistics
Kits support blood, saliva, and tissue with standardized collection protocols; nationwide couriers and validated cold-chain processes maintain sample integrity, with industry-preserved integrity rates exceeding 95% in 2024. Turnaround SLAs are tiered to clinical urgency—oncology samples prioritized for 24–48 hour processing—and visibility tools provide real-time notifications to clinicians at each step.
- Sample types: blood, saliva, tissue
- Integrity benchmark: >95% (2024)
- Coverage: nationwide courier networks
- Oncology SLA: 24–48 hours
- Real-time clinician notifications: near real-time tracking
Select international presence
Select international presence focuses on regions with supportive reimbursement and clinical guidelines, advancing expansion activity in 2024 into markets prioritizing genomic oncology. Local partners and accredited labs manage regulatory compliance and credentialing, while localized reports and multilingual support materials drive clinician adoption. Market entry emphasizes oncology centers of excellence to accelerate referrals and validation.
- Regions: reimbursement-aligned markets (2024 focus)
- Compliance: local lab partnerships for regulatory clearance
- Localization: translated reports + clinician support
- Channel: oncology centers of excellence prioritized
Kits >95% integrity, SLA 24–48h, NGS ~7d across ~4,500 hospitals
Sales/service teams target oncologists, OB/GYNs, PCPs and psychiatrists to drive adoption; kits (blood/saliva/tissue) use nationwide couriers, >95% integrity (2024) and oncology SLAs of 24–48h with median NGS ~7 days. EHR/FHIR integrations (96% hospital EHR adoption; CMS FHIR mandate 2021) enable e-consent, automated eligibility and real-time results across ~4,500 hospitals/networks (63% US hospitals).
| Metric | Value |
|---|---|
| Integrity | >95% (2024) |
| NGS median TAT | ~7 days |
| Oncology SLA | 24–48h |
| Hospitals covered | ~4,500 (~63% US) |
| EHR adoption | 96% (ONC) |
What You Preview Is What You Download
Myriad 4P's Marketing Mix Analysis
The preview shown here is the exact Myriad 4P's Marketing Mix Analysis you’ll receive after purchase—fully complete and editable. No samples or mockups: download the identical, high-quality document instantly at checkout and use it immediately for strategy or presentations. Buy with confidence.
Promotion
Evidence-led medical education
Evidence-led medical education is supported by 30+ peer-reviewed publications, 15 conference posters and 4 real-world studies (2024) showing a 22% increase in actionable diagnostic yield; KOL forums and 24 webinars in 2024 translate evidence into practice; accredited CME programs raise guideline adherence by ~18%, with consistent messaging on clinical utility and outcomes.
Field sales and clinical liaisoning
Specialist reps engage providers with case studies and workflow demos, accelerating adoption—Myriad reported FY2024 revenue of about $624 million, underscoring commercial reach. Clinical liaisons assist with test selection and interpretation, reducing inappropriate orders. Office training cuts ordering errors and delays, while relationship-building drives repeat utilization and higher lifetime value.
Patient awareness and advocacy
Digital content clarifies who should test and how results guide care, noting that 5–10% of cancers are hereditary. Partnerships with advocacy groups extend reach and build trust through co-branded education. Clear eligibility and financial assistance messaging reduces barriers to testing. Patient testimonials illustrate real-world impact and drive engagement.
Conferences and professional societies
Presence at ASCO (≈40,000 attendees), ACOG (≈7,000), APA (≈10,000) and genetics meetings (ASHG ≈7,000) drives visibility; symposia and booths (sponsorships $100k–$500k, booths $50k–$200k) showcase new data and products. Materials emphasize society guideline alignment; targeted follow-up campaigns convert ≈5% of leads into adoption, increasing uptake and revenue.
- ASCO ≈40,000
- ACOG ≈7,000
- APA ≈10,000
- Symposia $100k–$500k; booths $50k–$200k
- Follow-up conversion ≈5%
Payer and employer engagement
Health economic models show cost-effectiveness with a modeled 25% reduction in adverse events and a 3.2x ROI from employer pilots (2024). Value dossiers drove 92% payer coverage renewals in 2023–24. Employer programs positioned testing as a precision benefit, yielding 18% uptake among self-insured employers in pilot cohorts.
- 25% adverse-event reduction
- 3.2x pilot ROI
- 92% coverage renewals
- 18% employer uptake
Promotion: 22% diagnostic uplift; FY2024 revenue $624M
Promotion leverages 30+ publications, 24 webinars and KOL forums to drive a 22% increase in diagnostic yield and support FY2024 revenue ≈$624M; targeted reps, clinical liaisons and CME raise guideline adherence ~18% and lift adoption. Value dossiers secured 92% payer renewals; employer pilots show 3.2x ROI and 18% uptake.
| Metric | Value |
|---|---|
| Diagnostic yield uplift | 22% |
| FY2024 revenue | $624M |
| Payer renewals | 92% |
| Pilot ROI | 3.2x |
Price
Insurance-aligned pricing
Contracted rates are calibrated to documented medical necessity and policy coverage, reducing out-of-pocket surprises and aligning reimbursements with CPT-driven valuation. Prior authorization and benefits verification—used for roughly 80% of specialty services in 2024—streamline patient access and lower claim delays. Integrated coding support cuts denials within industry averages of 5–12% (HFMA 2023–24), while tiered pricing offers deeper discounts for higher-complexity panels.
Patient assistance programs
Myriad offers income-based assistance that lowers out-of-pocket costs for eligible patients, with transparent pre-test cost estimates provided before testing. Flexible payment plans help spread expenses to reduce financial stress, and policies are designed to avoid surprise billing by confirming patient responsibility up front.
Bundled and panel-based options
Bundled and panel-based pricing combines related genes or indications to deliver value, often yielding a 30–50% lower per-gene cost versus single-gene billing. Reflex testing rules (eg, automatic reflex to sequencing only after abnormal screen) can cut downstream testing spend by ~40%. Add-on modules enable tailored expansion without full-panel pricing, and structures are calibrated to balance clinical breadth with affordability.
Value-based and outcomes contracts
Agreements link reimbursement to utilization and clinical endpoints, tying payment to measurable outcomes. Pilots with health systems report 10–30% reductions in adverse events and 8–20% cost declines. Shared-savings models incentivize guideline-concordant use; CMS ACOs have produced multi-billion-dollar savings in recent years. Reporting dashboards track performance in near real-time.
- reimbursement tied to endpoints
- pilots: 10–30% fewer adverse events; 8–20% lower costs
- shared-savings → guideline adherence
- real-time dashboards for KPIs
Transparent cash-pay alternatives
Clear self-pay prices target the estimated 8–9% of U.S. patients who were uninsured in 2023–2024, offering published rates that match insured pricing logic to avoid balance billing and support predictability. An online checkout option streamlines transactions and mirrors consumer preference for digital payments, while occasional targeted promotions under access initiatives lower upfront barriers without undermining payer-aligned pricing.
Prior auth ~80%; panel pricing 30–50% cut; reflex ~40% downstream
Contracted, CPT-aligned rates and prior auth (used ~80% of specialty services in 2024) reduce surprises and denials (coding support cuts denials to 5–12%). Tiered/panel pricing lowers per-gene cost 30–50%; reflex testing can cut downstream spend ~40%. Income-based aid and published self-pay parity (targets 8–9% uninsured 2023–24) improve access. Value contracts show 10–30% fewer adverse events and 8–20% cost reductions.
| Metric | Value |
|---|---|
| Prior auth use (2024) | ~80% |
| Denial rate with coding support | 5–12% |
| Per-gene cost reduction (panel) | 30–50% |
| Downstream spend cut (reflex) | ~40% |
| Uninsured US share (2023–24) | 8–9% |
| Value-contract outcomes | 10–30% fewer AEs; 8–20% lower costs |